ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

CMS Issues Coverage Decision For Provenge in Prostate Cancer

July 29, 2011

DCE Advisors approver New Grant Programs In Ovarian Cancer, Biostatistics, Biotech Transfer; Support Services Recompetitions

June 19, 1992

DCCP Board Gives Concept Approval to Noncompeting Contracts

June 17, 1983

Bush Appoints Kripke To President’s Cancer Panel

February 21, 2003

In Brief: NCAB to Hear Program Review, Reports On AIDs Monoclonal Antibodies, Cancer Research at Drew

November 25, 1983

Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive?

September 28, 2012